Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Aug
24
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo